At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 375 enrolled
Drug / intervention
Tradipitant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Efficacy Study of The Neurokinin-1 Receptor Antagonist VLY-686 in Patients With Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating Tradipitant and Placebo for Atopic Dermatitis. Completed, enrolled 375 participants across 70 sites.
Detailed Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartJul 2018
Primary CompletionDec 2019
TodayJul 2026
First PostedJun 26, 2018
Enrollment StartJul 9, 2018
Primary CompletionDec 27, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.0 years ago
Interventions
Tradipitantdrug
Oral Capsule
Placebodrug
Oral Capsule